Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality.
Butler, C.R., Ogilvie, K., Martinez-Alsina, L., Barreiro, G., Beck, E.M., Nolan, C.E., Atchison, K., Benvenuti, E., Buzon, L., Doran, S., Gonzales, C., Helal, C.J., Hou, X., Hsu, M.H., Johnson, E.F., Lapham, K., Lanyon, L., Parris, K., O'Neill, B.T., Riddell, D., Robshaw, A., Vajdos, F., Brodney, M.A.(2017) J Med Chem 60: 386-402
- PubMed: 27997172 
- DOI: 10.1021/acs.jmedchem.6b01451
- Primary Citation of Related Structures:  
5T1U, 5T1W, 5TFT, 5TFU - PubMed Abstract: 
A growing subset of β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease (AD) utilizes an anilide chemotype that engages a key residue (Gly230) in the BACE1 binding site. Although the anilide moiety affords excellent potency, it simultaneously introduces a third hydrogen bond donor that limits brain availability and provides a potential metabolic site leading to the formation of an aniline, a structural motif of prospective safety concern ...